search
Back to results

Impact of Atrio-ventricular Optimization With His Bundle Pacing on Treatment of Atrio-ventricular Dromotropathy

Primary Purpose

Atrioventricular Block, Atrioventricular Dyssynchrony

Status
Completed
Phase
Not Applicable
Locations
Slovenia
Study Type
Interventional
Intervention
His bundle pacing, AV optimized
Backup VVI pacing
Sponsored by
University Medical Centre Ljubljana
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atrioventricular Block focused on measuring AV block, His bundle pacing, AV dyssynchrony, AV optimization, AV dromotropathy, First degree AV block, Peak oxygen uptake

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • First OR second degree Mobitz type 1 atrioventricular block with a PR interval > 250 ms
  • left ventricular ejection fraction > 50%
  • echocardiographic criteria of atrioventricular dyssynchrony (diastolic filling time/RR interval ratio < 0,4 OR fusion of E and A waves OR diastolic mitral regurgitation)
  • symptoms on exertion (dyspnea, palpitations)
  • insufficient shortening of PR interval during exercise (PR interval > 200 ms at heart rate of 100 beats per minute)

Exclusion Criteria:

  • left ventricular ejection fraction < 50%
  • third degree atrioventricular block
  • atrial fibrillation
  • sinus node disease
  • left bundle branch block
  • right bundle branch block
  • ventricular arrhythmia that indicates implantation of cardioverter defibrillator
  • consumption of drugs that influence atrioventricular conduction
  • active bacterial infection
  • inability to undergo cardiopulmonary exercise test
  • anaemia (haemoglobin concentration < 100 g/L)
  • pregnancy

Sites / Locations

  • UMC Ljubljana

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

His bundle pacing, AV optimized

Backup VVI pacing

Arm Description

Pacemaker programmed to DDD mode with ventricular lead placed on the bundle of His and echocardiographically optimized AV delay.

Pacemaker programmed to ventricular only pacing with low base rate (40/min) to allow intrinsic rhythm.

Outcomes

Primary Outcome Measures

Changes in exercise capacity
Measured by peak oxygen consumption on cardiopulmonary exercise test
Changes in left ventricular stroke volume
Measured by echocardiography
Changes in quality of life using the 5 level EQ-5D questionnaire
EQ-5D is a standardized measure of health status consisting of 2 pages - the EQ-5D descriptive system (descriptive system with five levels) and the EQ visual analog scale ranging from 0 (worst state) to 100 (best state).

Secondary Outcome Measures

Changes in left ventricular volume
End diastolic volume measured echocardiographicaly with biplane Simpson method
Changes in left atrial volume
Left atrial volume indexed by body surface area measured by echocardiography
Changes in the measure of left ventricular mechanical dyssynchrony
Measured by mid-ventricular radial speckle-tracking strain with an anteroseptal to posterior wall delay (AS-P delay)
Changes in QRS complex width
Measured by electrocardiogram
Changes in pacing thresholds
Measured during device check
Changes in sensing of R wave
Measured during device check
Changes in lead impedance
Measured during device check
Fluoroscopy time
Time of fluoroscopy use during device implantation
Adverse events
Any of the following adverse events: pocket hematoma, pneumothorax, hemothorax, cardiac tamponade, lead dislocation, lead perforation, cardiac implantable device infection

Full Information

First Posted
August 26, 2020
Last Updated
February 15, 2023
Sponsor
University Medical Centre Ljubljana
search

1. Study Identification

Unique Protocol Identification Number
NCT04544345
Brief Title
Impact of Atrio-ventricular Optimization With His Bundle Pacing on Treatment of Atrio-ventricular Dromotropathy
Official Title
Impact of Atrio-ventricular Optimization With His Bundle Pacing on Treatment of Atrio-ventricular Dromotropathy
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
December 23, 2019 (Actual)
Primary Completion Date
September 13, 2022 (Actual)
Study Completion Date
January 4, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Medical Centre Ljubljana

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims to determine the clinical and hemodynamic benefit of atrio-ventricular (AV) resynchronization with His bundle pacing in patients with symptomatic first degree AV block.
Detailed Description
The term AV dyssynchrony was introduced by Salden F. and coauthors in 2018. It stands for the adverse effects of AV dyssynchrony due to PR interval prolongation. According to the ESC and ACC guidelines, severe first degree AV block is an IIa indication for permanent pacemaker implantation, yet data on these patients' clinical outcomes are scarce. To independently determine the impact of AV resynchronization, His bundle pacing will be used to avoid intraventricular desynchronization. Symptomatic patients with severe first-degree AV block and echocardiographically proven AV dyssynchrony will be included in the study. All patients will receive a dual-chamber pacemaker with an atrial lead positioned in the right atrium and ventricular lead placed on the bundle of His. In a single-blind cross-over design, patients will be randomized to AV sequential His bundle pacing with echo-guided AV optimization or back-up VVI pacing mode. Each study period will last for three months. At the end of both periods, cardiopulmonary exercise testing, complete echocardiographic study, and clinical evaluation will be performed. Peak oxygen uptake and echocardiography-based hemodynamic parameters in both periods will be compared.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrioventricular Block, Atrioventricular Dyssynchrony
Keywords
AV block, His bundle pacing, AV dyssynchrony, AV optimization, AV dromotropathy, First degree AV block, Peak oxygen uptake

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
His bundle pacing, AV optimized
Arm Type
Experimental
Arm Description
Pacemaker programmed to DDD mode with ventricular lead placed on the bundle of His and echocardiographically optimized AV delay.
Arm Title
Backup VVI pacing
Arm Type
Sham Comparator
Arm Description
Pacemaker programmed to ventricular only pacing with low base rate (40/min) to allow intrinsic rhythm.
Intervention Type
Device
Intervention Name(s)
His bundle pacing, AV optimized
Intervention Description
A Select Secure 3830 (Medtronic, MN, USA) pacing lead will be placed on the bundle of His. In case of unsuccessful His capture, left bundle branch area pacing is going to be targeted. Pacemaker will be programmed to a low base rate and a high tracking rate to allow for intrinsic sinus rhythm. AV delay will be optimized with echocardiography to the shortest AV delay without truncation of the A wave on transmitral pulse wave doppler.
Intervention Type
Device
Intervention Name(s)
Backup VVI pacing
Intervention Description
Pacemaker will be programmed to VVI (ventricular only) mode with low base rate as to allow for intrinsic sinus rhythm without AV optimization.
Primary Outcome Measure Information:
Title
Changes in exercise capacity
Description
Measured by peak oxygen consumption on cardiopulmonary exercise test
Time Frame
Baseline, 3 months, 6 months
Title
Changes in left ventricular stroke volume
Description
Measured by echocardiography
Time Frame
Baseline, 3 months, 6 months
Title
Changes in quality of life using the 5 level EQ-5D questionnaire
Description
EQ-5D is a standardized measure of health status consisting of 2 pages - the EQ-5D descriptive system (descriptive system with five levels) and the EQ visual analog scale ranging from 0 (worst state) to 100 (best state).
Time Frame
Baseline, 3 months, 6 months
Secondary Outcome Measure Information:
Title
Changes in left ventricular volume
Description
End diastolic volume measured echocardiographicaly with biplane Simpson method
Time Frame
Baseline, 3 months, 6 months
Title
Changes in left atrial volume
Description
Left atrial volume indexed by body surface area measured by echocardiography
Time Frame
Baseline, 3 months, 6 months
Title
Changes in the measure of left ventricular mechanical dyssynchrony
Description
Measured by mid-ventricular radial speckle-tracking strain with an anteroseptal to posterior wall delay (AS-P delay)
Time Frame
Baseline, 3 months, 6 months
Title
Changes in QRS complex width
Description
Measured by electrocardiogram
Time Frame
Baseline, 3 months, 6 months
Title
Changes in pacing thresholds
Description
Measured during device check
Time Frame
Baseline, 3 months, 6 months
Title
Changes in sensing of R wave
Description
Measured during device check
Time Frame
Baseline, 3 months, 6 months
Title
Changes in lead impedance
Description
Measured during device check
Time Frame
Baseline, 3 months, 6 months
Title
Fluoroscopy time
Description
Time of fluoroscopy use during device implantation
Time Frame
Baseline
Title
Adverse events
Description
Any of the following adverse events: pocket hematoma, pneumothorax, hemothorax, cardiac tamponade, lead dislocation, lead perforation, cardiac implantable device infection
Time Frame
through study completion, an average of one year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: First OR second degree Mobitz type 1 atrioventricular block with a PR interval > 250 ms left ventricular ejection fraction > 50% echocardiographic criteria of atrioventricular dyssynchrony (diastolic filling time/RR interval ratio < 0,4 OR fusion of E and A waves OR diastolic mitral regurgitation) symptoms on exertion (dyspnea, palpitations) insufficient shortening of PR interval during exercise (PR interval > 200 ms at heart rate of 100 beats per minute) Exclusion Criteria: left ventricular ejection fraction < 50% third degree atrioventricular block atrial fibrillation sinus node disease left bundle branch block right bundle branch block ventricular arrhythmia that indicates implantation of cardioverter defibrillator consumption of drugs that influence atrioventricular conduction active bacterial infection inability to undergo cardiopulmonary exercise test anaemia (haemoglobin concentration < 100 g/L) pregnancy
Facility Information:
Facility Name
UMC Ljubljana
City
Ljubljana
ZIP/Postal Code
1000
Country
Slovenia

12. IPD Sharing Statement

Plan to Share IPD
Yes
Citations:
PubMed Identifier
29186415
Citation
Salden FCWM, Kutyifa V, Stockburger M, Prinzen FW, Vernooy K. Atrioventricular dromotropathy: evidence for a distinctive entity in heart failure with prolonged PR interval? Europace. 2018 Jul 1;20(7):1067-1077. doi: 10.1093/europace/eux207.
Results Reference
background
PubMed Identifier
23677846
Citation
Aro AL, Anttonen O, Kerola T, Junttila MJ, Tikkanen JT, Rissanen HA, Reunanen A, Huikuri HV. Prognostic significance of prolonged PR interval in the general population. Eur Heart J. 2014 Jan;35(2):123-9. doi: 10.1093/eurheartj/eht176. Epub 2013 May 14.
Results Reference
background
PubMed Identifier
10666756
Citation
Iliev II, Yamachika S, Muta K, Hayano M, Ishimatsu T, Nakao K, Komiya N, Hirata T, Ueyama C, Yano K. Preserving normal ventricular activation versus atrioventricular delay optimization during pacing: the role of intrinsic atrioventricular conduction and pacing rate. Pacing Clin Electrophysiol. 2000 Jan;23(1):74-83. doi: 10.1111/j.1540-8159.2000.tb00652.x.
Results Reference
background
PubMed Identifier
23801827
Citation
European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA); Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013 Aug;15(8):1070-118. doi: 10.1093/europace/eut206. Epub 2013 Jun 24. No abstract available.
Results Reference
background
PubMed Identifier
12495391
Citation
Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, Kutalek SP, Sharma A; Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002 Dec 25;288(24):3115-23. doi: 10.1001/jama.288.24.3115.
Results Reference
background
PubMed Identifier
27855853
Citation
Kiehl EL, Makki T, Kumar R, Gumber D, Kwon DH, Rickard JW, Kanj M, Wazni OM, Saliba WI, Varma N, Wilkoff BL, Cantillon DJ. Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. Heart Rhythm. 2016 Dec;13(12):2272-2278. doi: 10.1016/j.hrthm.2016.09.027.
Results Reference
background
PubMed Identifier
25446158
Citation
Sharma PS, Dandamudi G, Naperkowski A, Oren JW, Storm RH, Ellenbogen KA, Vijayaraman P. Permanent His-bundle pacing is feasible, safe, and superior to right ventricular pacing in routine clinical practice. Heart Rhythm. 2015 Feb;12(2):305-12. doi: 10.1016/j.hrthm.2014.10.021. Epub 2014 Oct 22.
Results Reference
background
PubMed Identifier
29535066
Citation
Abdelrahman M, Subzposh FA, Beer D, Durr B, Naperkowski A, Sun H, Oren JW, Dandamudi G, Vijayaraman P. Clinical Outcomes of His Bundle Pacing Compared to Right Ventricular Pacing. J Am Coll Cardiol. 2018 May 22;71(20):2319-2330. doi: 10.1016/j.jacc.2018.02.048. Epub 2018 Mar 10.
Results Reference
background
PubMed Identifier
19723701
Citation
Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W; MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009 Oct 1;361(14):1329-38. doi: 10.1056/NEJMoa0906431. Epub 2009 Sep 1.
Results Reference
background
PubMed Identifier
24963007
Citation
Kutyifa V, Stockburger M, Daubert JP, Holmqvist F, Olshansky B, Schuger C, Klein H, Goldenberg I, Brenyo A, McNitt S, Merkely B, Zareba W, Moss AJ. PR interval identifies clinical response in patients with non-left bundle branch block: a Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy substudy. Circ Arrhythm Electrophysiol. 2014 Aug;7(4):645-51. doi: 10.1161/CIRCEP.113.001299. Epub 2014 Jun 24.
Results Reference
background
PubMed Identifier
25921348
Citation
Joshi NP, Stopper MM, Li J, Beshai JF, Pavri BB. Impact of baseline PR interval on cardiac resynchronization therapy outcomes in patients with narrow QRS complexes: an analysis of the ReThinQ Trial. J Interv Card Electrophysiol. 2015 Aug;43(2):145-9. doi: 10.1007/s10840-015-9999-y. Epub 2015 Apr 29.
Results Reference
background
PubMed Identifier
28575215
Citation
Zhang J, Guo J, Hou X, Wang Y, Qian Z, Li K, Ge P, Zou J. Comparison of the effects of selective and non-selective His bundle pacing on cardiac electrical and mechanical synchrony. Europace. 2018 Jun 1;20(6):1010-1017. doi: 10.1093/europace/eux120.
Results Reference
background

Learn more about this trial

Impact of Atrio-ventricular Optimization With His Bundle Pacing on Treatment of Atrio-ventricular Dromotropathy

We'll reach out to this number within 24 hrs